来那度胺、硼替佐米和地塞米松诱导治疗及风险适配维持治疗在新诊断多发性骨髓瘤中的长期随访结果
该研究连续纳入2007年1月至2016年8月接受RVD诱导治疗的1000例新诊断多发性骨髓瘤患者,中位随访67个月。移植后98.5%患者总体缓解,89.9%达非常好的部分缓解及以上,33.3%达严格完全缓解。全队列中位无进展生存65个月,中位总生存126.6个月;高危与标危患者5年总生存率分别为57%和81%。
要点
- RVD诱导后移植后非常好的部分缓解及以上率达89.9%,严格完全缓解率33.3%。
- 全队列中位无进展生存65个月,高危40.3个月,标危76.5个月。
- 全队列中位总生存126.6个月,高危78.2个月,标危未达到。
核心结论
- RVD诱导治疗可使近90%患者移植后达非常好的部分缓解及以上,风险适配维持治疗可带来前所未有的长期结局。
- 该研究为迄今报道的最大RVD治疗队列,长随访显示三药诱导方案能为新诊断多发性骨髓瘤患者带来显著生存获益。
研究设计与样本
- 描述性研究,连续纳入2007年1月至2016年8月在本机构接受RVD诱导治疗的1000例新诊断多发性骨髓瘤患者。
- 人口学与临床特征及结局数据来自经机构审查委员会批准的骨髓瘤数据库。
- 缓解与进展按国际骨髓瘤工作组统一缓解标准评估。
主要发现
- 诱导治疗后总体缓解率97.1%,移植后98.5%。
- 中位随访67个月时,移植后89.9%患者达非常好的部分缓解及以上,33.3%达严格完全缓解。
- 全队列估计中位无进展生存65个月(95%CI 58.7至71.3个月),高危患者40.3个月(95%CI 33.5至47个月),标危患者76.5个月(95%CI 66.9至86.2个月)。
- 全队列中位总生存126.6个月(95%CI 113.3至139.8个月),高危患者78.2个月(95%CI 62.2至94.2个月),标危患者未达到。
- 高危与标危患者5年总生存率分别为57%和81%,10年总生存率分别为29%和58%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The combination of lenalidomide, bortezomib, and dexamethasone (RVD) is a highly effective and convenient induction regimen for both transplantation-eligible and -ineligible patients with myeloma. Here, we present the largest cohort of patients consecutively treated with RVD induction therapy followed by risk-adapted maintenance therapy with the longest follow-up and important information on long-term outcomes. PATIENTS AND METHODS: We describe 1,000 consecutive patients with newly diagnosed myeloma treated with RVD induction therapy from January 2007 until August 2016. Demographic and clinical characteristics and outcomes data were obtained from our institutional review board-approved myeloma database. Responses and progression were evaluated per International Myeloma Working Group Uniform Response Criteria. RESULTS: The overall response rate was 97.1% after induction therapy and 98.5% after transplantation, with 89.9% of patients achieving a very good partial response (VGPR) or better and 33.3% achieving stringent complete response after transplantation at a median follow-up time of 67 months. The estimated median progression-free survival time was 65 months (95% CI, 58.7 to 71.3 months) for the entire cohort, 40.3 months (95% CI, 33.5 to 47 months) for high-risk patients, and 76.5 months (95% CI, 66.9 to 86.2 months) for standard-risk patients. The median overall survival (OS) time for the entire cohort was 126.6 months (95% CI, 113.3 to 139.8 months). The median OS for high-risk patients was 78.2 months (95% CI, 62.2 to 94.2 months), whereas it has not been reached for standard-risk patients. Five-year OS rates for high-risk and standard-risk patients were 57% and 81%, respectively, and the 10-year OS rates were 29% and 58%, respectively. CONCLUSION: RVD is an induction regimen that delivers high response rates (VGPR or better) in close to 90% of patients after transplantation, and risk-adapted maintenance can deliver unprecedented long-term outcomes. This study includes the largest cohort of patients treated with RVD reported to date with long follow-up and demonstrates the ability of 3-drug induction regimens in patients with newly diagnosed multiple myeloma to result in a substantial survival benefit.
引用
- Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2020. PMID: 32298201. doi:10.1200/JCO.19.02515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。